ADMA Biologics, Inc. (ADMA) Q1 2018 Earnings Results

ADMA Biologics Misses on EPS, Stock Up 5.41%

ADMA Biologics reported a loss per share of $0.39, but the stock still rose by 5.41%. This increase may reflect investor optimism about future product developments and regulatory milestones, despite the lack of revenue figures and specific guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.39	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about the company's direction. They are focused on product development and regulatory progress.

Management highlighted ongoing efforts to enhance product offerings.

They emphasized the importance of upcoming regulatory milestones.

The team expressed confidence in future growth despite current challenges.

ADMA Biologics Misses on EPS, Stock Up 5.41%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Up 5.41%

Key numbers

Management commentary